Co-Authors
This is a "connection" page, showing publications co-authored by François Chappuis and Laurent Kaiser.
Connection Strength
0.586
-
Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs. Front Med (Lausanne). 2021; 8:685124.
Score: 0.060
-
Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov; 27(11):1695.e7-1695.e12.
Score: 0.060
-
Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2. PLoS One. 2021; 16(6):e0253321.
Score: 0.060
-
Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study. BMJ Open. 2021 06 18; 11(6):e044242.
Score: 0.059
-
Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nat Commun. 2021 06 08; 12(1):3455.
Score: 0.059
-
SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees. PLoS One. 2021; 16(4):e0250021.
Score: 0.059
-
Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers. PLoS One. 2021; 16(3):e0248921.
Score: 0.059
-
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis. 2021 05; 21(5):600-601.
Score: 0.058
-
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. BMJ Open. 2020 11 12; 10(11):e040110.
Score: 0.057
-
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 08 01; 396(10247):313-319.
Score: 0.055